Franco-American strategic research partnership to develop Alzheimer's therapies

10 January 2018
2019_biotech_test_vial_discovery_big

Just as US pharma giant Pfizer (NYSE: PFE) says it is pulling out of the Alzheimer’s and Parkinson’s disease discovery space, and Axovant Sciences (Nasdaq: AXON) reported a serious setback in its dementia program, a new Franco-American research partnership has been announced in this difficult sector, which has seen a number of other high-profile failures.

French pharma firm Servier and USA-headquartered biotech Treventis, both privately-owned, announced a strategic research partnership in targeting misfolded proteins implicated in neurodegenerative diseases.

The collaboration covers a large drug discovery program targeting both tau and amyloïde-β (Aβ), two key proteins involved in Alzheimer’s disease. This therapeutic strategy aims to provide patients with a drug that slows the progression of pathology in the brain, thereby minimizing functional decline through a disease-modifying mechanism.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology